Vladimir Makarov

Cleveland Clinic — United States

Medicine · Health Sciences

29h-index26.6kcitations43works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(21), Immunotherapy and Immune Responses(15), Cancer Genomics and Diagnostics(14), Lung Cancer Treatments and Mutations(5), CAR-T cell therapy research(5)

Publications43 total

FLIM-Based Metabolic Profiling of Endothelial Cells: Differentiating Alzheimer’s Disease from Healthy States
Photodiagnosis and Photodynamic Therapy·2025Open Access
DJ-1 deficiency and aging: dual drivers of retinal mitochondrial dysfunction
SSRN Electronic Journal·2025Open Access
Genomic Landscape of Superficial Malignant Peripheral Nerve Sheath Tumor
Laboratory Investigation·2024· 2 cited
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
Nature Genetics·2022· 74 citedOpen Access
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Nature Biotechnology·2021· 255 citedOpen Access
Resource-efficient pooled sequencing expands translational impact in solid tumors
Kidney Cancer Journal·2021· 1 citedOpen Access
Resource-efficient pooled sequencing expands translational impact in solid tumors
2021Open Access
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas
Clinical Cancer Research·2021· 16 citedOpen Access
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
Nature Cancer·2020· 192 citedOpen Access
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
Clinical Cancer Research·2020· 214 citedOpen Access
RIG-I Activation Is Critical for Responsiveness to Checkpoint Blockade
Blood·2019· 3 cited
Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
Nature Medicine·2019· 303 citedOpen Access
RIG-I activation is critical for responsiveness to checkpoint blockade
Science Immunology·2019· 128 citedOpen Access
Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma
Journal of Clinical Investigation·2019· 197 citedOpen Access
Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
Science·2019· 564 citedOpen Access
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
Nature Medicine·2019· 371 cited
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Nature Biotechnology·2018· 302 cited
Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes
Cancer Cell·2018· 273 citedOpen Access
Merkel Cell Carcinoma Patients Presenting Without a Primary Lesion Have Elevated Markers of Immunity, Higher Tumor Mutation Burden, and Improved Survival
Clinical Cancer Research·2017· 66 citedOpen Access
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Science·2017· 1.1k cited
page 1 of 3Next →

Frequent Co-authors

Timothy A. Chan(34), Nadeem Riaz(22), Luc G.T. Morris(13), Jedd D. Wolchok(10), Fengshen Kuo(10), Jonathan J. Havel(9), Taha Merghoub(9), Alexis Desrichard(9), Naiyer A. Rizvi(7), Alexandra Snyder(7), Diego Chowell(6), Robert Samstein(6), Sviatoslav M. Kendall(5), Nils Weinhold(5), Vinod P. Balachandran(5), Ahmet Zehir(5), Chirag Krishna(5), Matthew D. Hellmann(4), Logan A. Walsh(4), Michael A. Postow(4)